Abstract
Purpose: :
To analyze the effect of Suramab and Bevacizumab to inhibit angiogenesis and lymphangiogenesis in the cornea.
Methods: :
Corneal neovascularization was induced in three groups of nine White New Zealand rabbits, applying a filter paper disc soaked in 1M Na (OH) on the central cornea. Group 1 was treated after injury with intravenous Suramab (S) at a doses equivalent to 3mg/kg of Bevacizumab and 10mg/kg of Suramin, Group 2 was treated with intravenous Bevacizumab (B) at a doses of 3mg./kg, and Group 3 did not receive any treatment. Corneal sections were inmunohistochemically analysed with primary antibodies Lyve-1 (lymphatic vascular endothelial marker) and Pecam as an endothelial marker. The jimage program was used to calculate hematological and lymphatic vascularized areas.
Results: :
The area of immunoreactivity for blood vessels was smaller in treated groups (S: 0.76mm²; B: 0.95 mm²) compared to controls (3.4 mm²) . The area stained with Lyve-1 was significantly reduced in suramab (0.56 mm²) group than that found in Bevacizumab (1.62mm²) and control animals (2.8mm²) (p<0.05).
Conclusions: :
Intravenous Suramab and Bevacizumab inhibit angiogenesis and lymphangiogenesis in the cornea, although the effect of Suramab is stronger.
Keywords: cornea: clinical science • neovascularization • drug toxicity/drug effects